Mabpharm Limited Stock

2181

KYG5780F1046

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. 12:08:09 02/10/2026 +04			5-day change	1st Jan Change
0.4900 ^HKD	+8.89%		-3.92%	-2.00%

08-28	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-24	Mabpharm Limited Receives Approval for New Drug Application of CMAB807X (Denosumab Injection)	CI

Mabpharm Ltd is an investment holding company primarily engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Companyâ€™s main products include CMAB009 Enlituo (cetuximab Î² injection), CMAB007 Aomaishu (Omalizumab Î± for Injection), CMAB008 Leiting (infliximab for injection) and other products. The Companyâ€™s products are mainly used for colorectal cancer, asthma, urticaria, rheumatoid arthritis, ulcerative colitis in adults and other diseases. The Company is also engaged in the transfer of intellectual property. The Company mainly conducts its business in the domestic market.

Employees

394

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
02/10/26	HK$0.4900	+8.89%	2,000
30/09/26	HK$0.4500	-5.26%	56,000
29/09/26	HK$0.4750	-4.04%	0
28/09/26	HK$0.4950	-2.94%	0
25/09/26	HK$0.5100	+29.11%	16,000

Delayed Quote Hong Kong S.E.

More quotes

Market Cap	1.73B 2.02B 258M 229M 214M 195M 367M 24.76B 371M 2.58B 1B 12.66B 967M 946M 40.62B	P/E 2024	-8.48x	P/E 2025	44.9x
Enterprise Value	1.94B 2.28B 290M 258M 240M 219M 413M 27.87B 417M 2.91B 1.13B 14.25B 1.09B 1.07B 45.73B	EV / Sales 2024	5.06x	EV / Sales 2025	3.2x
Free-Float	22.82%	Yield 2024 *	-	Yield 2025	-

08-28	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-24	Mabpharm Limited Receives Approval for New Drug Application of CMAB807X (Denosumab Injection)	CI
06-09	Mabpharm Limited Receives Approval For New Drug Application Of CMAB807 Denosumab Injection From National Medical Products Administration	CI
06-09	Mabpharm's Application for Osteoporosis Drug Approved in China	MT
03-26	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-26	Mabpharm FY profit and total comprehensive income attributable rmb57.1 million	RE
12-05	Mabpharm Limited Announces Change of Address of Principal Place of Business in Hong Kong	CI
31/10/25	Mabpharm Limited Announces Board and Committee Changes, Effective October 31, 2025	CI
28/08/25	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
27/03/25	Mabpharm Shrinks Loss by 39% in 2024	MT
26/03/25	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03/01/25	Mabpharm's Infliximab Drug Receives Approval from Pakistan's Drug Regulator	MT
02/01/25	Mabpharm Limited Announces Approval from the Drug Regulatory Authority of Pakistan on the Registration of Core Product, CMAB008 (Infliximab for Injection)	CI

13/11/23	Cryopyrin-Associated Periodic Syndrome Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	AQ
20/07/21	Mabpharm : Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter	AQ
30/04/21	Mabpharm : POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, APRIL 30, 2021	PU
21/04/21	Mabpharm : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 18, 2021	PU
12/04/21	Mabpharm : (1) DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF CMAB807 (2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE CLINICAL TRIALS AGREEMENT AND THE CDMO AGREEMENT AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING	PU

1 day	+8.89%
1 week	-3.92%
Current month	+8.89%
1 month	+10.11%
3 months	+24.05%
6 months	-2.00%
Current year	-2.00%

1 week	0.45	0.54
1 month	0.35	0.54
Current year	0.31	0.81
1 year	0.31	0.81
3 years	0.25	0.94
5 years	0.25	1.2
10 years	0.25	1.8

Mabpharm Limited Stock

Stocks

2181

KYG5780F1046

Biotechnology & Medical Research

Valuation: Mabpharm Limited

Chart: Mabpharm Limited

Latest news: Mabpharm Limited

Press Releases: Mabpharm Limited

Quotes and Performance

Price Extremes

Managers and Directors: Mabpharm Limited

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Manager	Title	Age	Since
Hao Wang CEO	Chief Executive Officer	57	28/10/2020
Sheng Hou PRN	Corporate Officer/Principal	49	01/12/2023
Jing Tao PRN	Corporate Officer/Principal	53	03/08/2018

Director	Title	Age	Since
Hao Wang BRD	Director/Board Member	57	20/07/2018
Yun Feng Li BRD	Director/Board Member	49	20/07/2018
Shu Ge Jiao CHM	Chairman	60	20/07/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MABPHARM LIMITED	+8.89%	-3.92%	-24.62%	+3.16%	258M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-3.11%	-3.53%	+20.19%	+81.44%	57.39B
LONZA GROUP AG	+0.89%	-0.63%	+2.17%	+36.19%	47.64B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+342.39%	+742.40%	44.29B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+24.96%	+35.38%	42.5B
BEONE MEDICINES AG	-0.20%	-0.77%	+4.13%	+105.50%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.33%	+22.72%	28.53B
BIONTECH SE	+0.05%	-1.64%	-8.14%	-11.37%	24.34B
Average	+0.69%	-0.92%	+44.91%	+116.00%	39.08B
Weighted average by Cap.	+0.13%	-0.84%	+56.90%	+138.17%

	2024	2025
Net sales	258M 302M 38.51M 34.22M 31.94M 29.11M 54.9M 3.7B 55.41M 387M 150M 1.89B 145M 141M 6.07B	646M 756M 96.36M 85.62M 79.91M 72.84M 137M 9.26B 139M 967M 375M 4.74B 362M 354M 15.2B
Net income	-128M -150M -19.08M -16.96M -15.82M -14.42M -27.2M -1.83B -27.46M -192M -74.21M -938M -71.65M -70.09M -3.01B	57.13M 66.87M 8.52M 7.57M 7.07M 6.44M 12.15M 819M 12.26M 85.52M 33.14M 419M 31.99M 31.3M 1.34B
Net Debt	222M 260M 33.15M 29.45M 27.49M 25.05M 47.25M 3.19B 47.69M 333M 129M 1.63B 124M 122M 5.23B	217M 255M 32.44M 28.82M 26.9M 24.52M 46.24M 3.12B 46.67M 326M 126M 1.59B 122M 119M 5.12B